Acceleron Pharma Inc. Expected to Post Q2 2017 Earnings of ($0.62) Per Share (XLRN)
Acceleron Pharma Inc. (NASDAQ:XLRN) – Equities researchers at FBR & Co issued their Q2 2017 earnings per share estimates for Acceleron Pharma in a research note issued on Friday. FBR & Co analyst E. White forecasts that the brokerage will post earnings per share of ($0.62) for the quarter. FBR & Co currently has a “Buy” rating on the stock.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.02. The firm earned $3 million during the quarter, compared to the consensus estimate of $4.08 million. Acceleron Pharma had a negative return on equity of 30.75% and a negative net margin of 229.77%.
XLRN has been the subject of several other research reports. BTIG Research began coverage on shares of Acceleron Pharma in a report on Friday, August 19th. They issued a “buy” rating and a $46.00 price target for the company. Morgan Stanley reiterated a “buy” rating and issued a $58.00 price target on shares of Acceleron Pharma in a report on Friday, August 5th. Credit Suisse Group AG reiterated a “buy” rating and issued a $42.00 price target on shares of Acceleron Pharma in a report on Wednesday, September 28th. Zacks Investment Research upgraded shares of Acceleron Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, October 12th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Acceleron Pharma in a report on Friday, October 7th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Acceleron Pharma has an average rating of “Buy” and an average target price of $47.11.
Acceleron Pharma (NASDAQ:XLRN) opened at 37.96 on Monday. Acceleron Pharma has a one year low of $22.67 and a one year high of $50.86. The company’s market cap is $1.43 billion. The company has a 50-day moving average of $31.91 and a 200 day moving average of $32.90.
In other Acceleron Pharma news, Director Jean George sold 857,145 shares of the stock in a transaction on Friday, September 30th. The shares were sold at an average price of $35.50, for a total value of $30,428,647.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP John D. Quisel sold 45,952 shares of the stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $38.05, for a total transaction of $1,748,473.60. Following the completion of the sale, the senior vice president now owns 77,004 shares of the company’s stock, valued at approximately $2,930,002.20. The disclosure for this sale can be found here. 12.20% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Fund Advisors boosted its stake in shares of Acceleron Pharma by 16.2% in the first quarter. BlackRock Fund Advisors now owns 1,070,110 shares of the biopharmaceutical company’s stock worth $28,240,000 after buying an additional 149,193 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Acceleron Pharma by 8.7% in the second quarter. Nationwide Fund Advisors now owns 25,951 shares of the biopharmaceutical company’s stock worth $882,000 after buying an additional 2,077 shares in the last quarter. Acrospire Investment Management LLC purchased a new stake in shares of Acceleron Pharma during the second quarter worth approximately $110,000. Alps Advisors Inc. boosted its stake in shares of Acceleron Pharma by 25.3% in the second quarter. Alps Advisors Inc. now owns 52,287 shares of the biopharmaceutical company’s stock worth $1,777,000 after buying an additional 10,569 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of Acceleron Pharma during the second quarter worth approximately $570,000. Hedge funds and other institutional investors own 75.50% of the company’s stock.
About Acceleron Pharma
Acceleron Pharma Inc is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia.
Receive News & Stock Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related stocks with our FREE daily email newsletter.